AU2017326173B2 - Platform for activation and expansion of virus-specific T-cells - Google Patents

Platform for activation and expansion of virus-specific T-cells Download PDF

Info

Publication number
AU2017326173B2
AU2017326173B2 AU2017326173A AU2017326173A AU2017326173B2 AU 2017326173 B2 AU2017326173 B2 AU 2017326173B2 AU 2017326173 A AU2017326173 A AU 2017326173A AU 2017326173 A AU2017326173 A AU 2017326173A AU 2017326173 B2 AU2017326173 B2 AU 2017326173B2
Authority
AU
Australia
Prior art keywords
cells
virus
peptides
stimulating
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017326173A
Other languages
English (en)
Other versions
AU2017326173A1 (en
Inventor
Natalia LAPTEVA DOYLE
Cliona M. Rooney
Sandhya Sharma
Dimitrios WAGNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU2017326173A1 publication Critical patent/AU2017326173A1/en
Application granted granted Critical
Publication of AU2017326173B2 publication Critical patent/AU2017326173B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2017326173A 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific T-cells Active AU2017326173B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395438P 2016-09-16 2016-09-16
US62/395,438 2016-09-16
PCT/US2017/051284 WO2018052947A1 (en) 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific t-cells

Publications (2)

Publication Number Publication Date
AU2017326173A1 AU2017326173A1 (en) 2019-04-11
AU2017326173B2 true AU2017326173B2 (en) 2022-08-18

Family

ID=61619728

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017326173A Active AU2017326173B2 (en) 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific T-cells

Country Status (10)

Country Link
US (2) US20190194619A1 (enExample)
EP (1) EP3512531A4 (enExample)
JP (1) JP7002769B2 (enExample)
KR (1) KR102501827B1 (enExample)
CN (1) CN110177558B (enExample)
AU (1) AU2017326173B2 (enExample)
CA (1) CA3036966A1 (enExample)
NZ (1) NZ751571A (enExample)
TW (1) TWI780069B (enExample)
WO (1) WO2018052947A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP4089167A1 (en) 2012-02-09 2022-11-16 Baylor College of Medicine Pepmixes to generate multiviral ctls with broad specificity
EP3350600A4 (en) 2015-09-18 2019-04-17 Baylor College of Medicine DISTINCTION OF AN IMMUNOGENIC ANTIGEN OF A PATHOGEN AND CORRELATION WITH CLINICAL EFFECTIVENESS
US9642906B2 (en) * 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2019202118A1 (en) * 2018-04-20 2019-10-24 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
CN108841792A (zh) * 2018-06-14 2018-11-20 浙江大学 靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用
EP4458419A3 (en) * 2018-09-10 2025-01-08 Atara Biotherapeutics, Inc. Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
US10772914B1 (en) * 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
WO2022056285A1 (en) * 2020-09-10 2022-03-17 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
AU2020369573A1 (en) * 2019-10-23 2022-03-24 Cue Biopharma, Inc. Modified cytotoxic T cells and methods of use thereof
EP4061386A4 (en) * 2019-11-19 2024-01-10 Acibadem Labmed Saglik Hizmetleri Anonim Sirketi METHOD FOR PRODUCING MULTIVIRUS-SPECIFIC T CELLS
CN114945382A (zh) 2019-11-26 2022-08-26 诺华股份有限公司 Cd19和cd22嵌合抗原受体及其用途
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
JP2023548382A (ja) * 2020-10-28 2023-11-16 ティエスディ・ライフ・サイエンシーズ・カンパニー・リミテッド 異種免疫細胞に対する化学走性を誘導する形質転換された免疫細胞
EP4330379A2 (en) * 2021-04-27 2024-03-06 Baylor College of Medicine Virus-specific immune cells expressing chimeric antigen receptors
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
KR20250024750A (ko) 2022-04-13 2025-02-19 티크바 알로셀 피티이. 엘티디. 치료용 t 세포 산물
EP4509137A1 (en) * 2023-06-14 2025-02-19 Kuiper, Inc. A chimeric antigen receptor combinatorial multi-antigen targeted allogeneic t cell immunotherapy with reduced risk of t cell exhaustion, host versus graft rejection, and graft versus host disease
GB202318977D0 (en) * 2023-12-12 2024-01-24 Swarm Oncology Ltd Method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155594A1 (en) 2001-03-27 2002-10-24 Hsieh Helen V. Method and apparatus for culturing cells
CA2618580A1 (en) 2005-08-08 2007-02-15 Fondazione Centro San Raffaele Del Monte Tabor Use of common .gamma. chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
PT2856876T (pt) * 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
EP2065462A1 (en) * 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
EP3101122B1 (en) * 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
KR102117350B1 (ko) * 2010-04-13 2020-06-02 이뮤노베이티브 테라피스, 엘티디. 조절 t 세포들의 저해를 위한 방법 및 조성물
SG11201404677TA (en) * 2011-12-12 2014-11-27 Cell Medica Ltd Process of expanding t cells
EP4089167A1 (en) * 2012-02-09 2022-11-16 Baylor College of Medicine Pepmixes to generate multiviral ctls with broad specificity
KR101545217B1 (ko) * 2012-10-29 2015-08-18 연세대학교 산학협력단 줄기세포의 미분화 배양 및 분화 증진을 위한 폴리도파민-펩타이드 고정화 표면 기질 및 그 제조 방법
CN105335280A (zh) * 2014-07-16 2016-02-17 北京奇虎科技有限公司 程序性能测试方法和装置
WO2016044811A1 (en) 2014-09-19 2016-03-24 City Of Hope COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
US12478670B2 (en) * 2015-03-20 2025-11-25 Children's National Medical Center Generating HPV antigen-specific T cells from a naïve T cell population
WO2016183153A1 (en) * 2015-05-12 2016-11-17 Memorial Sloan Kettering Cancer Center Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
JP6799895B2 (ja) * 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． ＴＣＲγδ＋Ｔ細胞の生産方法
KR102444170B1 (ko) * 2016-06-27 2022-09-16 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 기억 t 세포로부터 생성된 베토 세포

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D TESCHNER ET AL, BONE MARROW TRANSPLANTATION, GB, 2013, vol. 49, no. 1, pages 138 - 144 *
M. BLEAKLEY ET AL, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,2014,vol. 20, no. 5, pages 705-716 *
S. LAM ET AL, JPT PEPTIDE TECHNOLOGIES, 2015, pages 1-2 *
W. JIANG ET AL, JOURNAL OF VIROLOGY., 2014, vol. 88, no. 10, pages 5369 - 5380 *

Also Published As

Publication number Publication date
KR20190051039A (ko) 2019-05-14
TW201814041A (zh) 2018-04-16
AU2017326173A1 (en) 2019-04-11
CN110177558A (zh) 2019-08-27
KR102501827B1 (ko) 2023-02-22
TWI780069B (zh) 2022-10-11
US20220251509A1 (en) 2022-08-11
NZ751571A (en) 2025-10-31
EP3512531A4 (en) 2020-03-11
US20190194619A1 (en) 2019-06-27
CN110177558B (zh) 2025-02-28
WO2018052947A1 (en) 2018-03-22
JP2019531722A (ja) 2019-11-07
CA3036966A1 (en) 2018-03-22
EP3512531A1 (en) 2019-07-24
JP7002769B2 (ja) 2022-02-04

Similar Documents

Publication Publication Date Title
US20220251509A1 (en) Platform for activation and expansion of virus-specific t-cells
US11981923B2 (en) Pepmixes to generate multiviral CTLS with broad specificity
US10500265B2 (en) Generation of HPV-specific T-cells
Leen et al. Antiviral T‐cell therapy
US10857182B2 (en) Generation and use in adoptive immunotherapy of stem cell-like memory T cells
JP2025028931A (ja) Ｅｂｖ特異的免疫細胞
Sili et al. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant
Münz Epstein–Barr virus pathogenesis and emerging control strategies
Aspord et al. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases
NZ791258A (en) Platform for activation and expansion of virus-specific t-cells
Chen et al. EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein
HK40084539A (en) Pepmixes to generate multiviral ctls with broad specificity
Withers Third-party virus-specific T-cells can provide long-term viral control without toxicity in allogeneic haemopoietic stem cell transplant patients with recurrent or refractory viral infection
HK40020879A (en) Pepmixes to generate multiviral ctls with broad specificity
HK40020879B (en) Pepmixes to generate multiviral ctls with broad specificity
Zecca et al. Possible alternatives to antimicrobial therapies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)